From the bench to the bedside—promoting the roles of nurses and allied health professionals in the management of lung cancer and mesothelioma

Por White, John
Publicado no Transl Lung Cancer Res (2016)

Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer

Por Malhotra, Jyoti, Jabbour, Salma K.
Publicado no Transl Lung Cancer Res (2018)

Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?

Por Chatwal, Monica S., Tanvetyanon, Tawee
Publicado no Transl Lung Cancer Res (2018)

EGFR-TKIs in EGFR-mutated lung cancer: Setting the new standard for 1(st) line therapy

Por Wolf, Jürgen
Publicado no Transl Lung Cancer Res (2012)

Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?

Por Dempke, Wolfram C. M., Fenchel, Klaus
Publicado no Transl Lung Cancer Res (2017)

ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients

Por Bagai, Rakesh, Pennell, Nathan A.
Publicado no Transl Lung Cancer Res (2013)

Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy?

Por Slotman, Berend J., van Tinteren, Harm
Publicado no Transl Lung Cancer Res (2015)

New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer

Por Whitsett, Timothy G., Loftus, Joseph C., Winkles, Jeffrey A., Tran, Nhan L.
Publicado no Transl Lung Cancer Res (2013)

Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions

Por Warren, Graham W., Ward, Kenneth D.
Publicado no Transl Lung Cancer Res (2015)

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Por Jabbour, Salma K., Berman, Abigail T., Simone, Charles B.
Publicado no Transl Lung Cancer Res (2017)

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning

Por Klempner, Samuel J., Raufi, Alexander, Ou, Sai-Hong Ignatius
Publicado no Transl Lung Cancer Res (2015)

Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer

Por Lee, Howard J., Zeng, Jing, Rengan, Ramesh
Publicado no Transl Lung Cancer Res (2018)

Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer

Por Horinouchi, Hidehito
Publicado no Transl Lung Cancer Res (2016)

Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a word of caution

Por Varela, Gonzalo, Gómez-Hernández, María Teresa
Publicado no Transl Lung Cancer Res (2016)

Sestrin2 expression is a favorable prognostic factor in patients with non-small cell lung cancer

Por Chen, Kuan-Bing, Xuan, Ying, Shi, Wen-Jun, Chi, Feng, Xing, Rui, Zeng, Yue-Can
Publicado no Am J Transl Res (2016)

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Por Taunk, Neil K., Rimner, Andreas, Culligan, Melissa, Friedberg, Joseph S., Brahmer, Julie, Chaft, Jamie
Publicado no Transl Lung Cancer Res (2017)

Role of PET/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging

Por Greenspan, Bennett S.
Publicado no Transl Lung Cancer Res (2017)

CHRNA3 rs1051730 polymorphism and lung cancer susceptibility in Asian population: a meta-analysis

Por Zhan, Ping, Song, Yong
Publicado no Transl Lung Cancer Res (2015)

Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?

Por Lo Russo, Giuseppe, Proto, Claudia, Garassino, Marina Chiara
Publicado no Transl Lung Cancer Res (2016)

Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer

Por Buttigliero, Consuelo, Bertaglia, Valentina, Novello, Silvia
Publicado no Transl Lung Cancer Res (2016)